AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Sophia Frentzas; Tarek Meniawy; Steven Chuan-Hao Kao; Ruihua Wang; Yunxia Zuo; Hao Zheng; Wei Tan

doi:10.1200/JCO.2021.39.15_suppl.2583

AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

Sophia Frentzas, Tarek Meniawy, Steven Chuan-Hao Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, Wei Tan

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	39
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2021.39.15_suppl.2583
Publication status	Published - 20 May 2021

Access to Document

10.1200/JCO.2021.39.15_suppl.2583

Cite this

@article{730e5efc1a204473b6e5aeb52747d609,

title = "AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.",

author = "Sophia Frentzas and Tarek Meniawy and Kao, {Steven Chuan-Hao} and Ruihua Wang and Yunxia Zuo and Hao Zheng and Wei Tan",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15_suppl.2583",

language = "English",

volume = "39",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

AdvanTIG-105 : Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors. / Frentzas, Sophia; Meniawy, Tarek; Kao, Steven Chuan-Hao et al.

In: Journal of Clinical Oncology, Vol. 39, No. 15, 20.05.2021.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - AdvanTIG-105

T2 - Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

AU - Frentzas, Sophia

AU - Meniawy, Tarek

AU - Kao, Steven Chuan-Hao

AU - Wang, Ruihua

AU - Zuo, Yunxia

AU - Zheng, Hao

AU - Tan, Wei

PY - 2021/5/20

Y1 - 2021/5/20

U2 - 10.1200/JCO.2021.39.15_suppl.2583

DO - 10.1200/JCO.2021.39.15_suppl.2583

M3 - Abstract/Meeting Abstract

VL - 39

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

SN - 0732-183X

IS - 15

ER -